Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
Active, not recruiting · NCT04006262 · Registry updated 2025-06-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 25 |
15 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Léon Bérard | Lyon | France | 77 |
| CHRU Jean Minjoz | Besançon | France | 11 |
| CHRU Lille | Lille | France | 32 |
| CHU Nantes | Nantes | France | 86 |
| CHU Poitiers | Poitiers | France | 70 |
| CHU Pontchaillou Rennes | Rennes | France | 1 |
| CHU Toulouse | Toulouse | France | 76 |
| Hôpital Européen Geroges Pompidou | Paris | France | 1 |
| Hôpital Henri Mondor | Créteil | France | 27 |
| Hôpital privé Jean Mermoz | Lyon | France | 18 |
| Hôpital Saint Antoine | Paris | France | 21 |
| Hôpital Saint Louis | Paris | France | 21 |
| ICM Val d'Aurelle | Montpellier | France | 6 |
| Institut Hospitalier Franco-Britannique | Levallois-Perret | France | 7 |
| Institut Mutualiste Montsouris | Paris | France | 29 |